FDA, NIH Partner for Rare Neurodegenerative Disease Research

The Food and Drug Administration and the National Institutes of Health have launched a public-private partnership for rare neurodegenerative diseases, according to a Wednesday news release.

The Critical Path for Rare Neurodegenerative Diseases partnership, which will be convened by the Critical Path Institute, aims to advance the understanding of neurodegenerative diseases and help develop treatments, the administration said.

This story was produced by Bloomberg Law Automation.